Studies | Reference type | Cases | Mean age | Female patient | Anesthesia | Drug dose of FNB | Drug dose of SNB | Drug dose of LIA | Concomitant Pain | Follow-up |
---|---|---|---|---|---|---|---|---|---|---|
(SNB/LIA) | (SNB/LIA) | (SNB/LIA) | ||||||||
Tanikawa 2014 [11] | RCT | 23/23 | 72/71 | 19/20 | General anesthesia | 20 ml of 0.375% ropivacaine | 20 ml of 0.375% ropivacaine | 200 mg of ropivacaine and 0.5 ml of adrenaline | IV ketorolac 30 mg, ketoprofen 100 mg, or diclofenac 75 mg | 3 months |
Gi 2014 [13] | RCT | 24/25 | 78/77 | 21/24 | General anesthesia | 20 ml 0.375% ropivacaine | 20 ml 0.375% ropivacaine | 60 ml 0.5% ropivacaine with 0.3 mg epinephrine | 400 mg celecoxib, 20 mg oxycontin, and a 6 mg scopolamine patch topically | 1 month |
Safa 2014 [12] | RCT | 33/32 | 61/61 | 18/15 | Spinal anesthesia | 20 mL of 0.5% ropivacaine | 20 mL of 0.5% ropivacaine | 50 mL of 0.2% ropivacaine | Celecoxib 200 mg, gabapentin 200 mg and acetaminophen 1 g | 1.5–3 months |
Nagafuchi 2015 [14] | RCT | 17/16 | 72/73 | 15/13 | General anesthesia | 20 mL of 0.375% ropivacaine | 20 ml of 0.375% ropivacaine | 100 mL of 0.2% ropivacaine | Celecoxib 200 mg, gabapentin 200 mg and acetaminophen 1 g | 1 months |
Cip 2016 [15] | Non-RCT | 16/18 | 73.4/71.8 | 12/11 | Spinal or general anesthesia | 0.2% ropivacaine (4 ml/h) | 20 ml ropivacaine 0.2% | 0.33% ropivacaine (5 mL/h) | Celecoxib and Oxycodone | NS |
Aikawa 2016 [16] | Non-RCT | 23/23 | 72/71 | 19/20 | general anesthesia | 20 ml 0.375% ropivacaine | 20 ml 0.375% ropivacaine | 20 mL of 0.375% levobupivacaine | NS | 6 months |